Radioimmunotargeting with I-131 labeled chimeric G250 monoclonal antibody in patients with renal cell carcinoma.

被引：0
|
作者：
Steffens, MG [1 ]
Boerman, OC [1 ]
Oosterwijk, E [1 ]
Oosterhof, GON [1 ]
Witjes, JA [1 ]
OosterwijkWakka, JC [1 ]
Koenders, E [1 ]
Debruyne, FMJ [1 ]
Corstens, FHM [1 ]
机构：
[1] UNIV NIJMEGEN HOSP,6500 HB NIJMEGEN,NETHERLANDS
来源：
JOURNAL OF NUCLEAR MEDICINE | 1996年 / 37卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：740 / 740
页数：1
相关论文
共 50 条
  • [1] Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250
    Steffens, MG
    Boerman, OC
    OosterwijkWakka, JC
    Oosterhof, GON
    Witjes, JA
    Koenders, EB
    Oyen, WJG
    Buijs, WCAM
    Debruyne, FMJ
    Corstens, FHM
    Oosterwijk, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1529 - 1537
  • [2] Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma.
    Divgi, CR
    O'Donoghue, JA
    McGagh, DA
    Motzer, RJ
    Anwar, K
    Sheikh, A
    Gonzalez, RS
    Welt, S
    Old, LJ
    Larson, SM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 217P - 217P
  • [3] Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
    Steffens, MG
    Boerman, OC
    de Mulder, PHM
    Oyen, WJG
    Buijs, WCAM
    Witjes, JA
    van den Broek, WJM
    Oosterwijk-Wakka, JC
    Debruyne, FMJ
    Corstens, FHM
    Oosterwijk, E
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3268S - 3274S
  • [4] Phase I/II radioimmunotherapy with I-131 labeled chimeric monoclonal antibody cG250 in patients with metastasized renal cell carcinoma.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oyen, WJG
    De Mulder, PHM
    Witjes, JA
    Oosterhof, GON
    Debruyne, FMJ
    Corstens, FHM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 247P - 247P
  • [5] Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In:: An intrapatient comparison
    Brouwers, AH
    Buijs, WCAM
    Oosterwijk, E
    Boerman, OC
    Mala, C
    De Mulder, PHM
    Corstens, FHM
    Mulders, PFA
    Oyen, WJG
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3953S - 3960S
  • [6] SCINTIGRAPHY OF RENAL-CELL CARCINOMA WITH I-131-LABELED MONOCLONAL-ANTIBODY (MAB) G250
    DIVGI, CR
    OOSTERWIJK, E
    SCOTT, AM
    BANDER, N
    OOSTERWIJK, J
    WELT, S
    LARSON, SM
    OLD, LJ
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1992, 19 (08): : 576 - 576
  • [7] Red marrow dosimetry after administration of I-131 labeled chimeric G250 monoclonal antibody (cG250) in patients with renal cell carcinoma, based on planar gamma camera images.
    Buijs, WCAM
    Steffens, MG
    Boerman, O
    Siegel, JA
    Oosterwijk, E
    Corstens, FHM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 958 - 958
  • [8] Fractionated radioimmunotherapy with I-131 chimeric antibody G250 (cG250) in metastatic renal cancer
    Divgi, CR
    O'Donoghue, JA
    McGagh, D
    Anwar, K
    Motzer, R
    Welt, S
    Larson, SM
    Old, LJ
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1158 - 1158
  • [9] A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    Bleumer, I
    Knuth, A
    Oosterwijk, E
    Hofmann, R
    Varga, Z
    Lamers, C
    Kruit, W
    Melchior, S
    Mala, C
    Ullrich, S
    De Mulder, P
    Mulders, PFA
    Becks, J
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 985 - 990
  • [10] Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
    Divgi, CR
    Bander, NH
    Scott, AM
    O'Donoghue, JA
    Sgouros, G
    Welt, S
    Finn, RD
    Morrissey, F
    Capitelli, P
    Williams, JM
    Deland, D
    Nakhre, A
    Oosterwijk, E
    Gulec, S
    Graham, MC
    Larson, SM
    Old, LJ
    [J]. CLINICAL CANCER RESEARCH, 1998, 4 (11) : 2729 - 2739
12345